Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
29%(4 trials)

Phase Distribution

Ph phase_3
4
25%
Ph phase_4
4
25%
Ph not_applicable
3
19%
Ph early_phase_1
1
6%
Ph phase_1
1
6%
Ph phase_2
3
19%

Phase Distribution

2

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
3(18.8%)
Phase 3Large-scale testing
4(25.0%)
Phase 4Post-market surveillance
4(25.0%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(14)
Terminated(1)
Other(1)

Detailed Status

Completed14
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 11 (6.3%)
Phase 23 (18.8%)
Phase 34 (25.0%)
Phase 44 (25.0%)
N/A3 (18.8%)

Trials by Status

completed1488%
unknown16%
withdrawn16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT04918823Phase 1

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

Completed
NCT05743764Phase 3

HU007 in Patients with Dry Eye Syndrome

Completed
NCT05184517Early Phase 1

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers

Completed
NCT03597139Phase 2

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Completed
NCT02004067Phase 4

Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease

Completed
NCT03461575Phase 3

Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

Completed
NCT01817582Phase 2

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Completed
NCT02917512Phase 2

Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome

Completed
NCT03403023Not Applicable

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Unknown
NCT00405431Not Applicable

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

Completed
NCT01695668Not Applicable

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Completed
NCT02492412Phase 3

Efficacy and Safety of HE10 for Dry Eye Syndrome

Completed
NCT02461719Phase 3

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

Completed
NCT02028312Phase 4

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Withdrawn
NCT00407043Phase 4

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Completed
NCT00567983Phase 4

Topical Cyclosporine and Disease Progression

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16